GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » Gross Margin %

Deciphera Pharmaceuticals (FRA:D05) Gross Margin % : 96.30% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Deciphera Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was €42.6 Mil. Deciphera Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €44.3 Mil. Therefore, Deciphera Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 96.30%.


The historical rank and industry rank for Deciphera Pharmaceuticals's Gross Margin % or its related term are showing as below:

FRA:D05' s Gross Margin % Range Over the Past 10 Years
Min: 93.46   Med: 97.34   Max: 99.47
Current: 97.72


During the past 9 years, the highest Gross Margin % of Deciphera Pharmaceuticals was 99.47%. The lowest was 93.46%. And the median was 97.34%.

FRA:D05's Gross Margin % is ranked better than
99.09% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.8 vs FRA:D05: 97.72

Deciphera Pharmaceuticals had a gross margin of 96.30% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Deciphera Pharmaceuticals was 0.00% per year.


Deciphera Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Deciphera Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Gross Margin % Chart

Deciphera Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only - 99.47 96.95 93.46 97.72

Deciphera Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.07 98.54 99.55 97.03 96.30

Competitive Comparison of Deciphera Pharmaceuticals's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Gross Margin % falls into.



Deciphera Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Deciphera Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=146.4 / 149.797
=(Revenue - Cost of Goods Sold) / Revenue
=(149.797 - 3.422) / 149.797
=97.72 %

Deciphera Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=42.6 / 44.286
=(Revenue - Cost of Goods Sold) / Revenue
=(44.286 - 1.637) / 44.286
=96.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Deciphera Pharmaceuticals  (FRA:D05) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Deciphera Pharmaceuticals had a gross margin of 96.30% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Deciphera Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (FRA:D05) Business Description

Traded in Other Exchanges
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (FRA:D05) Headlines

No Headlines